About this Journal Submit a Manuscript Table of Contents

Molecular Imaging-Guided Theranostics and Personalized Medicine

Call for Papers

The rapid increase in the market for molecular imaging science enhances the opportunities in the development of new molecular imaging agents for diagnosis and therapy. New clinical indications using proteomic or genomic expression in oncology, as well as cardiology and neurology, also offer a stimulus. This promotes growth of procedure volume and sales of clinic imaging agents as well as development of new radiopharmaceuticals. The growing use of molecular imaging is also helping to control and monitor dosage for increased safety and effectiveness. For instance, molecular imaging in oncology has been focused on identification of tumor specific markers and the application of these markers for evaluation of patient response to radiation therapy, chemotherapy, or chemo/radiotherapy. Therefore, molecular imaging technologies play a major role to be able to provide personalized therapy for patients. The opportunity to use image-guiding to select patient for personalized therapy is truly the focus. The imaging findings could be integrated with metabolomics. In addition, theranostic concept is equally important in personalized therapy of diseases. The effort in image-guided cell therapy, theranostic approaches in parallel with instrumentation development, would be more accurate in the evaluation of patient response to treatment.

This special issue will provide new trends in molecular imaging agents and instrumentation development. This special issue will become the scientific tool for moving a concept from bench work to clinic product development. The special issue will be interesting to translational research scientists and support staff, such as clinicians, molecular biologists, imaging scientists, pharmaceutical developers, physicists, fellows, and staffs. Both academic and clinical scientists are invited to submit the manuscripts. Potential topics include, but are not limited to:

  • Image-guided theranostic approach of diseases
  • Advances in bioimaging applications in preclinical drug discovery
  • Advances in imaging instrumentation development
  • Hybrid imaging modalities in disease management
  • Theranostic agents development
  • Imaging technology in drug development
  • Validation of imaging agents on new molecular targets
  • Personalized drug development from molecular imaging
  • Link metabolomics and imaging molecular pathways

Before submission authors should carefully read over the journal's Author Guidelines, which are located at http://www.hindawi.com/journals/bmri/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/submit/journals/bmri/molecular.imaging/mig/ according to the following timetable:

Manuscript DueFriday, 3 May 2013
First Round of ReviewsFriday, 26 July 2013
Publication DateFriday, 20 September 2013

Lead Guest Editor

  • David J. Yang, University of Texas MD Anderson Cancer Center, Houston, TX, USA

Guest Editors

  • Fong Y. Tsai, Taipei Medical University and Neurosurgery and Surgery, University of California, Irvine, CA, USA
  • Tomio Inoue, Yokohama City University School of Medicine, 3-9 Fukuura Kanazawa-ku, Yokohama, Japan
  • Mei-Hsiu Liao, Radiopharmaceuticals Production and Marketing Center, Institute of Nuclear Energy Research, Atomic Energy Council, Taiwan
  • Fan-Lin Kong, University of Texas MD Anderson Cancer Center, Houston, TX, USA
  • Shaoli Song, Department of Nuclear Medicine, Ren Ji hospital, Shanghai JiaoTong University School of Medicine, China